🇺🇸 aripiprazole (Abilify) in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 3 reports (21.43%)
  2. Somnolence — 2 reports (14.29%)
  3. Speech Disorder — 2 reports (14.29%)
  4. Abdominal Discomfort — 1 report (7.14%)
  5. Abdominal Pain Lower — 1 report (7.14%)
  6. Adverse Reaction — 1 report (7.14%)
  7. Arthritis — 1 report (7.14%)
  8. Ascites — 1 report (7.14%)
  9. Blood Lactic Acid Abnormal — 1 report (7.14%)
  10. Blood Potassium Decreased — 1 report (7.14%)

Source database →

Other Psychiatry approved in United States

Frequently asked questions

Is aripiprazole (Abilify) approved in United States?

aripiprazole (Abilify) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for aripiprazole (Abilify) in United States?

Massachusetts General Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.